Latest from Clara Ashworth
Business
BridgeBio Pharma (BBIO) expects 2027 to mark its transformation from a one-product company into a group with four globally launched therapies, according to Thomas Trimarchi, its president and chief financial officer, speaking at a…
7 Oct 2026 Deals
Shares in Nanexa (NANEXA) more than doubled in early trading last month after the Swedish drug-delivery company signed a global licensing agreement with Novo Nordisk (NVO) worth up to about €1.17bn ($1.33bn).
6 Oct 2026 Deals
Dr Reddy's Laboratories (RDY) announced it had signed an agreement with Japanese drugmaker Takeda Pharmaceutical (TAK) to promote and distribute the Qdenga dengue vaccine in India.
2 Oct 2026 Business
Anthropic has quietly set up a laboratory for physical biology work, extending its artificial intelligence ambitions into drug science, according to two people familiar with the matter.
1 Oct 2026 Deals
Telix Pharmaceuticals (TLX) has agreed to acquire Germany's ITM Isotope Technologies Munich for about $1.65bn on a cash- and debt-free basis, in a deal that deepens the Australian company's push into radiopharmaceuticals.
29 Sep 2026 Deals
GE HealthCare (GEHC) is in talks over a possible deal worth about $1bn to acquire Sofie Biosciences, a developer of radioactive chemicals used in cancer imaging, according to people familiar with the matter.
24 Sep 2026 Business
GSK (GSK) will shut its vaccine manufacturing facility in Dresden, Germany, in the summer of 2027, the company announced, citing falling demand for traditional egg-based influenza vaccines. The closure puts 641 jobs at risk, according to…
21 Sep 2026 Deals
Apollo Global Management (APO) is in advanced discussions to acquire Johnson & Johnson's (JNJ) orthopedics unit in a deal that could value the business at close to $20 billion. An agreement could be reached within weeks, though J&J is also…
21 Sep 2026 Business
Ionis Pharmaceuticals (IONS) priced zilganersen, its newly approved treatment for Alexander disease, at $285,000 per dose, a day after U.S. regulators cleared the injectable drug as the first approved therapy for the rare genetic disorder…
18 Sep 2026 Business
Aspen Pharmacare (APNJ) expects African sales of Eli Lilly's (LLY) Mounjaro to exceed two billion rand ($124mn) in its current financial year, as soaring demand in South Africa is complemented by planned market entries in Nigeria and Kenya.
17 Sep 2026 Deals
India's Cipla (CIPL) has entered an exclusive licensing agreement with China's Qilu Pharmaceutical to commercialize a biosimilar version of Merck's (MRK) blockbuster cancer drug Keytruda in the United States, positioning both companies to…
16 Sep 2026 Deals
Spire Healthcare (SPI), the British private hospital operator, has agreed to be acquired by a consortium of investment funds comprising Toscafund Asset Management, Three Hills Capital Partners and Ares Management, in a transaction valuing…
14 Sep 2026 Deals
Kimberly-Clark (KMB) has filed for European Union regulatory approval of its proposed $40 billion acquisition of Kenvue (KVUE), according to documents published on the European Commission's website.
9 Sep 2026 Deals
Eli Lilly (LLY) has agreed to acquire privately held Merida Biosciences for up to $2.88bn in cash, bolstering its immunology pipeline with an experimental treatment for thyroid-related autoimmune conditions as the company accelerates its…
8 Sep 2026 Business
Pharmaceutical companies have sharply accelerated their embrace of artificial intelligence, striking a wave of partnerships and acquisitions since the start of 2025 as they seek to compress drug development timelines and reduce costs…
4 Sep 2026 Deals
Kimberly-Clark (KMB) has filed for European Union regulatory approval of its proposed $40bn acquisition of Kenvue (KVUE), according to documents published on the European Commission's website, as the consumer goods company advances its…
2 Sep 2026 Business
Eli Lilly (LLY) has launched Foundayo, its oral weight-loss and diabetes treatment, in the United Kingdom, making Britain the first country in Europe where the pill is available following regulatory approval earlier this month.
1 Sep 2026 Business
Nestlé is seeking to transform the rise of GLP-1 weight-loss drugs from an existential threat into a commercial opportunity, using artificial intelligence and nutritional science to develop products aimed at the growing cohort of consumers…
27 Aug 2026 Deals
Sandoz (SDZ) has agreed to pay up to $77mn upfront to Shanghai Henlius Biotech (2696) for licensing rights to three biosimilar drugs, as the Swiss generics group moves to expand its pipeline ahead of what it describes as an unprecedented…
26 Aug 2026 Deals
Jazz Pharmaceuticals (JAZZ) said it would acquire privately held Actio Biosciences in a transaction valued at up to $1.32bn, adding a clinical-stage treatment for a severe rare epilepsy with no approved therapies to its neuroscience…
21 Aug 2026